MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.09.24

MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.09.24 Share Price

DE000MB0BQQ2

Market Closed - Börse Stuttgart 11:49:38 05/07/2024 pm IST
0.158 ^EUR	+1.94%

Current month	-9.20%
1 month	+6.76%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.09.24

Latest news about AMGEN INC.

Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints	02/07	MT
Amgen Inc.(NasdaqGS:AMGN) added to Russell 1000 Dynamic Index	01/07	CI
Argus Raises Amgen's Price Target to $340 From $300	28/06	MT
Amgen CEO Bob Bradway’s Advice to Amgen’s Summer Interns: Don’t Hold Back	27/06	PU

More news

Quotes 5-day view

Date	Price	Change
05/24/05	0.158	+1.94%
04/24/04	0.155	+4.03%
03/24/03	0.149	-12.35%
02/24/02	0.17	-1.73%
01/24/01	0.173	-0.57%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 11:49 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Morgan Stanley
WKN	MB0BQQ
ISIN	DE000MB0BQQ2
Date issued	09/11/2022
Strike	400 $
Maturity	20/09/2024 (76 Days)
Parity	10 : 1
Emission price	1.1 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	1.36 €
Lowest since issue	0.065 €
Delta	0.08x
Omega	13.87
Premium	29.14x
Gearing	166.42x
Moneyness	0.7780
Difference Strike	89.12 $
Difference Strike %	+22.28%
Spread	0.029 €
Spread %	15.51%
Theoretical value	0.1725
Implied Volatility	36.74 %
Total Loss Probability	93.93 %
Intrinsic value	0.000000
Present value	0.1725
Break even	401.87 €
Theta	-0.03x
Vega	0.02x
Rho	0x

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

310.9 USD

Average target price

316.4 USD

Spread / Average Target

+1.79%

Consensus